135 related articles for article (PubMed ID: 38236562)
1. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
3. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
4. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, absorption, metabolism, and excretion of [
Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
7. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Pharmacokinetics, Biotransformation and Elimination of Pomotrelvir Orally Administered in Healthy Male Adults Using Two [
Yang Z; Wong SL; Cha D; Wilfret D; Turnquist D; Plummer A; van Ingen E; Kearney BP
Drug Metab Dispos; 2023 Dec; 51(12):1607-1614. PubMed ID: 37684056
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
[TBL] [Abstract][Full Text] [Related]
10. Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
Riska P; Lamson M; MacGregor T; Sabo J; Hattox S; Pav J; Keirns J
Drug Metab Dispos; 1999 Aug; 27(8):895-901. PubMed ID: 10421616
[TBL] [Abstract][Full Text] [Related]
11. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Subramanian R; Tang J; Zheng J; Lu B; Wang K; Yant SR; Stepan GJ; Mulato A; Yu H; Schroeder S; Shaik N; Singh R; Wolckenhauer S; Chester A; Tse WC; Chiu A; Rhee M; Cihlar T; Rowe W; Smith BJ
Mol Pharm; 2023 Dec; 20(12):6213-6225. PubMed ID: 37917742
[TBL] [Abstract][Full Text] [Related]
12. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
13. Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.
Cirillo I; Mannens G; Janssen C; Vermeir M; Cuyckens F; Desai-Krieger D; Vaccaro N; Kao LM; Devineni D; Redman R; Turner K
Antimicrob Agents Chemother; 2008 Oct; 52(10):3478-83. PubMed ID: 18644951
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and metabolism of [
Mancel V; Mathy FX; Boulanger P; English S; Croft M; Kenney C; Knott T; Stockis A; Bani M
Xenobiotica; 2017 Aug; 47(8):705-718. PubMed ID: 27489076
[TBL] [Abstract][Full Text] [Related]
15. Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers.
Shaw JP; Cheong J; Goldberg MR; Kitt MM
Antimicrob Agents Chemother; 2010 Aug; 54(8):3365-71. PubMed ID: 20516282
[TBL] [Abstract][Full Text] [Related]
16. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
17. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
18. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
[TBL] [Abstract][Full Text] [Related]
19. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Bhattacharya C; Sandinge AS; Bragg RA; Heijer M; Yan J; Andersson LC; Jurva U; Pelay-Gimeno M; Vaes WHJ; de Ligt RAF; Gränfors M; Amilon C; Lindstedt EL; Menakuru SR; Garkaviy P; Weidolf L; Gopaul VS
Drug Metab Dispos; 2023 Apr; 51(4):451-463. PubMed ID: 36639243
[TBL] [Abstract][Full Text] [Related]
20. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
